NDAORALTABLET
Approved
May 2006
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
9
Data completeness
7/8 — Comprehensive
AZILECT (rasagiline mesylate) by Teva is selective, irreversible mao-b inhibitor indicated for the treatment of idiopathic parkinson's disease. Approved for parkinson's disease. First approved in 2006.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AZILECT (rasagiline mesylate) is a selective, irreversible MAO-B inhibitor approved for idiopathic Parkinson's disease and multiple system atrophy. It works by inhibiting monoamine oxidase type B in the brain, increasing dopamine levels in the striatum to improve motor dysfunction. The drug is administered orally as a tablet.
$2MPart D
LOE ApproachingDeclining
1.3 years to LOEProduct approaching loss of exclusivity with modest market penetration (1,061 Part D claims in 2023), signaling shrinking brand team and transition to defensive positioning.
Mechanism of Action
selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson's disease. The results of a clinical trial designed to examine the effects of AZILECT on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be…
Indications (1)
Worked on AZILECT at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.